Spesolimab for Erythrodermic Pustular Psoriasis

Intravenous and subcutaneous spesolimab use in a medically comorbid patient with erythrodermic generalized pustular psoriasis

Case author Angad Arinder Chadha, MD, presents a case of a 72-year-old African American female admitted for management of a generalized pustular psoriasis (GPP) flare.

By Angad Arinder Chadha, MD

A 72-year-old African American female was admitted for management of a generalized pustular psoriasis (GPP) flare that had been ongoing for 4 weeks prior to admission. She had multiple underlying comorbid conditions including chronic obstructive pulmonary disease, chronic kidney disease, vascular dementia, type 2 diabetes, and diverticulitis. After failure of topical clobetasol ointment, she was given one dose of IV spesolimab 900 mg with rapid improvement in her pustular burden within 48 hours.

However, her clinical picture continued to deteriorate and was complicated by leukemoid reaction (WBC count 48.5 x 109), hypothermia, lactic acidosis, and distributive shock with multiorgan dysfunction with acute kidney injury and pulmonary edema necessitating intubation; these physiologic derangements were felt to be secondary to prolonged severe systemic inflammation due to untreated GPP for 4 weeks prior to admission.

All of these parameters improved with a 4-day course of systemic cyclosporine 5mg/kg, which was employed due to its potent and rapid anti-inflammatory effects. Given persistent erythema, she then received a second dose of IV spesolimab 900 mg, 7 days after her first dose.

As the patient and her daughter expressed a strong desire to avoid any future flares of her GPP, shared decision-making among the patient, her daughter, and the medical team led to the initiation of subcutaneous spesolimab 300 mg every 28 days to prevent future GPP flares. This was felt to be especially important in her case given the severity of her flare and the multiorgan dysfunction precipitated by the flare. The patient continues to do well on subcutaneous spesolimab to this day, which has been well tolerated despite her increasing medical complexity and multiple hospital admissions for other medical issues.

Physical Exam and Lab Results

On initial examination, the patient had robust generalized erythema >90% BSA with innumerable scattered pustules, many in arcuate arrangement. Initial lab testing showed an elevated white blood cell (WBC) count of 20.6 × 10⁹/L. By day 5, she experienced a markedly elevated WBC (48.5 × 10⁹/L), hypothermia (94.4°F), and acute kidney injury (peak serum creatinine 3.54 mg/dL).

Diagnostic Review

Skin biopsy results from her left forearm showed subcorneal pustules, dermal edema, and perivascular lymphocytic and interstitial neutrophilic inflammation. The usual differential of subcorneal pustules was considered, but none fit her condition (eg, acute generalized exanthematous pustulosis, candida infection, dermatitis herpetiformis, IgA pemphigus, impetigo).

The notable feature of this case is the fact that the patient had flaring GPP for 4 weeks before seeking medical care, which not only led to delay in treatment but also led to severe systemic inflammation; this unchecked inflammation ended up causing distributive shock (treated with cyclosporine) and created excess morbidity. The clinician needs to remember the systemic manifestations of severe psoriasis when treating severe pustular psoriasis. When left untreated, erythrodermic physiology due to generalized cutaneous vasodilation can result in high-output cardiac failure, dehydration, electrolyte imbalances, hypothermia, and sepsis, while chronic severe inflammation can result in anemia and malnutrition.

Which of the following patients with psoriasis would you strongly consider starting subcutaneous spesolimab for flare prevention?

A 75-year-old male with a history of chronic kidney disease, hyperlipidemia, hypertension, and GPP, who has severe GPP flares every 2 years that necessitate inpatient hospitalization and treatment with cyclosporine or acitretin

A 34-year-old female with a history of palmoplantar pustulosis that is well controlled on ixekizumab injections

A 65-year-old male with a history of erythrodermic plaque psoriasis that was previously well controlled on infliximab infusions but is currently quiescent off therapy

A 42-year-old male with a history of acrodermatitis continua of Hallopeau that is well controlled with topical clobetasol

A 22-year-old female who you are seeing for acne, who incidentally reports a family history of severe GPP in her father

Before & After Photos

Treatment Discussion and Outcome

It is imperative to diagnose GPP early and initiate appropriate treatment not only to treat the skin but prevent nonskin morbidity, as occurred in this patient. While some patients with milder presentation of pustular psoriasis may not require systemic treatment between pustular flares, flare prevention should be a cornerstone of treatment in GPP given the debilitating, life-limiting nature of GPP flares and the morbidity patients with GPP can face due to severe flares, especially with advancing age.

The patient in this case continues to do well on subcutaneous spesolimab, which has been well tolerated despite her increasing medical complexity and multiple hospital admissions for other medical issues.